Advertisement

Latest News

Achieving GC-Free IgG4-Related Disease Remission With Rilzabrutinib, with John Stone, MD, MPH

4 hours ago

Rilzabrutinib shows promising remission rates in IgG4-related disease with minimal glucocorticoid use, offering a safer oral treatment option.

J&J Submits sNDA to FDA for Lumateperone (CAPLYTA) to Prevent Schizophrenia Relapse

8 hours ago

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.

The Role of Biologic Therapies in Optometry with Walt Whitley, OD, MBA

8 hours ago

Whitley speaks to the plethora of available biologics, the choice paralysis that can accompany the wide range of options, and the future of the industry.

Cutting Down on Glucocorticoids in Giant Cell Arteritis With Upadacitinib, with Frank Buttgereit, MD

10 hours ago

New findings highlight upadacitinib's effectiveness in treating giant cell arteritis, showcasing lower infection rates and improved glucocorticoid tapering strategies.

Artificial Intelligence in Cataract Surgery and Optometry at Large with Harvey Richman, OD, and Rebecca Wartman, OD

11 hours ago

Drs. Richman and Wartman discuss the benefits of using predictive and diagnostic AI, while cautioning about the implicit risks of overreliance on early, imperfect technology.

Advertisement
Advertisement